The global montelukast intermediate market is a very niche market and a limited number of companies manufacture and market montelukast intermediates. Through extensive research, it is found that market players have adopted strategies such as product launches and collaborations with major players. On the basis of market study, we found some key players operating in this market which are VIVAN Life Sciences, P.G. Shah & Co., Manus Aktteva Biopharma LLP, Ortin Laboratories Limited, and others. The growth of these companies is majorly attributed to their high revenue growth, broad product portfolio, and wide global presence. The global montelukast intermediate market has a huge revenue base in major pharmaceutical markets including North America, Europe, and Asia-Pacific, with countries such as the US, France, the UK, India, and Africa being the major contributors
VIVAN Life Sciences is one of the leading players in the market with a strong customer base and market presence. The company has good research and development base and a strong product portfolio which provide a competitive advantage over other market players. Moreover, companies such as P.G. Shah & Co. are contributing to the growth of the market and catering to the needs of the customers by providing customization and establishing long term agreements with the customers. Manus Aktteva Biopharma LLP is a prominent player in the global montelukast intermediate market and is present in more than 50 countries covering major regions including Asia and Europe. Moreover, Ortin Laboratories Limited holds a significant market share in the global montelukast intermediate market and provides end to end services to customers in the market. The company also has its manufacturing unit which is WHO GMP Standards certified.
Many leading players are concentrated in the Asian region owing to the rising demand for asthma treatment, well-established markets, high healthcare expenditures, and numerous opportunities for growth. These companies have expanded their market in other regions as well. Major players in the market are investing a huge amount of money in research and development activities to launch better and cost-effective products in the montelukast intermediate market. They are also focusing on expanding their geographical boundaries by launching new products in emerging markets of developing countries.
Threat of New Entrants
The threat of new entrants is medium to high in the global montelukast intermediate market. Any contract development and manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of a product is low as compared to other industries. Montelukast intermediates are specialized and manufactured to be used in the manufacturing of pharmaceutical products. Moreover, the majority of the customers are using products of trusted sellers, and they are likely to prefer established brands over new market player due to quality concerns and to maintain the quality of final product, which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
The suppliers in the global montelukast intermediate market are raw material manufacturers. There are various suppliers present in the global montelukast intermediate market. Switching cost of these suppliers is low due to intense competition, and also the raw materials required for the manufacturing of montelukast intermediate are easily used. Moreover, suppliers are likely to enter into long term partnerships with montelukast intermediate manufacturers. Due to the increasing research and development activities related to the montelukast and entry of major pharmaceutical companies in the market, a large number of customers are available.
Moreover, several suppliers are there to cater to the needs of the customers which lead to intense competition between the existing suppliers. However, low-quality products are likely to damage the quality of the final product, and it can cause adverse effects. Hence, customers are selective about suppliers. Due to this, the overall bargaining power of suppliers in the global montelukast intermediate market is low.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global montelukast intermediate market. The market has a limited number of buyers and very few montelukast intermediate manufacturing companies to cater to the need of the buyers. However, the montelukast intermediate is specialized and play an important role in pharmaceutical product manufacturing, and the buyers of the montelukast intermediate are moderately inclined towards quality products manufactured by trusted companies. As the products are manufactured for the treatment of asthma, there are limited substitutes available in the market. Also, most of the buyers are pharmaceutical companies and research organizations; they are likely to enter into the long-term agreements with the montelukast intermediate manufacturers for uninterrupted supply. Moreover, they can exert pressure on the manufacturers due to the low switching cost and intense rivalry in the market, which is responsible for the increased bargaining power of buyers.
Threat of Substitutes
The threat of substitutes in the global montelukast intermediate market is low to moderate. Montelukast intermediates are used in the development and manufacturing of pharmaceutical products which are used for the treatment of asthma. There are limited options available in the market to serve the need of the customers and which eliminates the threat of substitute. However, the increasing research and development activities and demand for efficient intermediates are likely to provide new substitutes to the montelukast intermediate. Also, the high degree of switching cost decreases the threat of substitutes. The overall threat of substitutes in the global montelukast intermediate is low to moderate.
Intensity of Rivalry
The rivalry in the global montelukast intermediate market is moderate to high. The low degree of product differentiation and a limited number of customers increases the intensity of rivalry in the market. The market is growing with a prominent growth rate and likely to provide opportunities for major players to expand their geographical boundaries which will initiate cutthroat competition between major players to capture maximum market share in the emerging markets. Major players are trying to develop products under their own as a part of vertical integration. Players are engaged in developing a process to lower their manufacturing and logistics cost to increase profitability and to overcome the competition. Moreover, they are also developing advanced products for differentiating their brand from their competitors.
